TIMP1 and neoplasm: GPI-TIMP-1 was shown to inhibit the growth of fibrosarcomas and enhance the tumor sensitivity to doxorubicin treatment, also in vivo, when delivered directly to the tumor (30), thus circumventing loss of efficacy due to unspecific insertion in non-tumor membranes.